SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) and Royalty Pharma plc (RPRX) today announced they have entered into a strategic funding ...

BURLINGTON, ON, Jan. 26, 2026 /CNW/ - SIR Royalty Income Fund (TSX: SRV.UN) (the "Fund") today announced that, as of January 1, 2026, one new restaurant was added to the Royalty Pooled Restaurants ...

Royalty Pharma delivered robust FY25 results, with double-digit growth in Royalty Receipts and Portfolio Receipts. Check out why RPRX stock is a buy.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to ...

Royalty Pharma plc has completed a transaction to monetize remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in cash, resulting in total proceeds of $530 million ...

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...

Royalty Pharma (RPRX) and Denali Therapeutics (DNLI) announced a $275M synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead ...

Million Fund Targets Best-in-Class Mineral and Royalty Assets in the Permian Basin FORT WORTH, TX, UNITED STATES, ...

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) -- RTW Committed $75M in Launch ...

The board of SIR Royalty Income Fund (TSE:SRV.UN) has announced that it will pay a dividend of CA$0.105 per share on the 30th of January. This takes the dividend yield to 8.5%, which shareholders will ...